Clinical Trials Logo
  1. Home
  2. Erectile Dysfunction
  3. NCT05446493
  4. Details
NCT05446493 Clinical Trial

Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction

Erectile Dysfunction Clinical Trial

Official title:
Assessment of Serum YKL-40 Level and Platelets Indices Among Patients With Diabetic Erectile Dysfunction

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05446493
Other study ID # 346/3/19
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date April 1, 2019
Est. completion date January 5, 2022

Study information
Verified date July 2022
Source Aswan University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this current study is to estimate serum level of YKL-40, serum total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3 months.

Recruitment information / eligibility
Status Completed
Enrollment 60
Est. completion date January 5, 2022
Est. primary completion date March 15, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 30 Years to 70 Years
Eligibility Inclusion Criteria: - Diabetic patients with ED. Exclusion Criteria: - Patients with history of pelvic trauma. - Patients with major pelvic surgical intervention. - Patients with hypogonadism and hyperprolactinemia. - Patients with chronic liver disease. - Patients with cardio vascular system diseases. - History of chronic intake of central nervous system, anti androgen drugs or other drugs as Tramadol. - Smokers patients. - Patients with non-vasculogenic Erectile dysfunction.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Tadalafil 5mg
Estimate serum level of serum YKL-40, total testosterone and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil 5mg for 3months. Penile color Doppler ultrasound examination before and after treatment

Locations
Country Name City State
Egypt Aswan university Aswan

Sponsors (1)
Lead Sponsor Collaborator
Aswan University

Country where clinical trial is conducted

Egypt, 

Outcome
Type Measure Description Time frame Safety issue
Primary Serum YKL-40 and platelets indices in erectile dysfunction Measurement of YKL-40 and platelets indices in diabetic patients with erectile dysfunction treated by daily tadalafil. 3 months
Secondary Effect of tadalafil on Erectile dysfucntion patients To show the therapeutic effect of tadalafil in dose 5 mg daily on Erectile dysfucntion patients and assess their response by international index of erectile function (IIEF-5) 3 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05366504 - LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment Phase 2/Phase 3
Recruiting NCT02745808 - Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Recruiting NCT02573805 - the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males N/A
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Withdrawn NCT02579148 - Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes Phase 1
Recruiting NCT02225548 - Sagene 2014 - Parkinson's Disease and Erectile Dysfunction Phase 4
Completed NCT02587988 - Trial to Evaluate the Efficacy and Safety of HCP1302 Phase 3
Completed NCT02945462 - Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED) Phase 1
Completed NCT01937871 - A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED) Phase 3
Completed NCT01698684 - Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction Phase 4
Not yet recruiting NCT01321489 - A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies Phase 3
Completed NCT02226237 - Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy N/A
Terminated NCT01262833 - Pudendal Assessment in Erectile Dysfunction N/A
Completed NCT01230541 - Effect of Udenafil on Spermatogenesis Phase 1
Completed NCT01037218 - Treatment of Erectile Dysfunction II Phase 3
Completed NCT01037244 - Treatment of Erectile Dysfunction I Phase 3
Recruiting NCT00313898 - Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males Phase 4
Completed NCT00667979 - Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse Phase 4
Completed NCT00421083 - Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury Phase 3
Completed NCT00663728 - Assessment of Duration of Erection With Vardenafil 10 mg Phase 4